Visual Outcomes Of Extended Macular Vision Iol In Eyes With Stable Macular Disease

To study the effectiveness of the EyeMax Mono IOL, an extended macular vision IOL, implanted in eyes with stable macular disease undergoing phacoemulsification.

Single-center retrospective case series at Micro Chirurgia Oculare, Milan, Italy.

A retrospective case review of 170 eyes from 137 patients with stable macular disease (such as dry age-related macular degeneration, diabetic maculopathy, retinitis pigmentosa) undergoing phacoemulsification with implantation of the EyeMax Mono IOL (Sharpview Ophthalmology, London, UK), an extended macular vision IOL with improved image quality up to 10o from the fovea, between March 2016 and February 2020. Outcome measures were change in corrected distance visual acuity (CDVA) after surgery, postoperative refraction, and intraocular pressure with a 1.3x magnifier.

Mean follow-up time was 22±12 months (range: 0 to 47 months). Preoperative logMAR CDVA was 0.63±0.42 (n=169), which improved to 0.38±0.38 (n=169) (39.7%, p value <0.001) at the last follow up. 129 eyes (76.3%) gained >1 line in their CDVA, 25 eyes (14.8%) gained one line, 7 eyes (4%) stayed the same, 8 eyes (4.7%) lost lines. Greater improvements in visual acuity was observed in subjects with worse pre-operative visual acuity (r = 0.46; p <0.01). Ninety-seven eyes (97) had mild (visually insignificant) cortical cataract (LOCS III NC1): their CDVA improved from 0.6±0.4 to 0.37±0.36 (38.3%, p value <0.001), out of which 54 eyes (55.7%) gained ≥2lines. There were no intra- or post-operative complications.

EyeMax Mono extended macular vision IOL can effectively improve CDVA in patients with stable macular disease with good safety profile. The improvement of vision in eyes with visually insignificant cataract suggests that visual outcomes may exceed those obtained with standard IOLs in subjects with macular disease.